Scarica l'app Stockscreener
5.85
2.66%
-0.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MNKD Giù?
Forum
Previsione
Frazionamento azionario
Mannkind Corp Borsa (MNKD) Ultime notizie
Insider Sell: Stuart Tross Sells 47,006 Shares of MannKind Corp (MNKD) - GuruFocus
Mannkind’s chief people officer sells $297k in stock - Investing.com
MannKind Corp stock hits 52-week high at 6.33 USD By Investing.com - Investing.com Nigeria
Pharma news weekly roundup - The Pharma Letter
Is MannKind Corporation stock affected by interest rate hikesMarket Trend Review & Consistent Profit Alerts - ulpravda.ru
How MannKind Corporation stock reacts to Fed rate cutsJuly 2025 Snapshot & Safe Swing Trade Setups - ulpravda.ru
Why MannKind Corporation stock is favored by top institutions2025 Biggest Moves & High Yield Equity Trading Tips - ulpravda.ru
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report - Stocktwits
Boeing’s CEO Tells Staff ‘Important Work Ahead’ To Continue Its Turnaround: Report - Stocktwits
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 - Stocktwits
MannKind stock jumps on 2026 catalysts - Investing.com
Can MannKind Corporation stock deliver surprise earnings beatInsider Buying & Advanced Technical Analysis Signals - ulpravda.ru
MannKind outlines 2026 growth drivers with key FDA decisions ahead - Investing.com
MannKind Provides Business Updates and 2026 Growth Drivers - Yahoo Finance Singapore
MannKind Corp Is Suddenly Everywhere – Is MNKD the Next Sleeper Stock You’ll Regret Ignoring? - AD HOC NEWS
MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care - Finviz
12 Best NASDAQ Stocks to Buy in 2026 - Insider Monkey
MannKind (MNKD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MNKD (MannKind) ROCE % : 17.64% (As of Sep. 2025) - GuruFocus
Even though MannKind (NASDAQ:MNKD) has lost US$61m market cap in last 7 days, shareholders are still up 80% over 5 years - Yahoo Finance
180 Wealth Advisors LLC Increases Stock Position in MannKind Corporation $MNKD - MarketBeat
How Pediatric FUROSCIX Expansion And New Patents At MannKind (MNKD) Has Changed Its Investment Story - simplywall.st
MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors? - Stocktwits
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - Yahoo Finance
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares? - The Motley Fool
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
FDA approves FUROSCIX for pediatric patients weighing 43kg or more By Investing.com - Investing.com South Africa
FDA approves FUROSCIX for pediatric patients weighing 43kg or more - Investing.com
MannKind Corporation Announces FDA Approval of FUROSCIX® for Pediatric Use and Patent Issuance for FUROSCIX ReadyFlow™ Autoinjector - Quiver Quantitative
Shot for fluid buildup could help kids and work at home in 10 seconds - Stock Titan
Can MannKind Corporation stock hit record highs again2025 Valuation Update & Consistent Growth Stock Picks - ulpravda.ru
Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock - MarketBeat
Insider Sell: Michael Castagna Sells 65,804 Shares of MannKind C - GuruFocus
How MannKind Corporation stock performs in weak economyMarket Growth Report & Weekly Top Gainers Alerts - Улправда
Insider Sell: Michael Castagna Sells 42,116 Shares of MannKind C - GuruFocus
MannKind Corporation (NASDAQ:MNKD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
MannKind (NASDAQ: MNKD) adds audited and pro forma scPharma results to merger filing - Stock Titan
MannKind (MNKD): Evaluating Valuation After FDA Acceptance of the FUROSCIX ReadyFlow Autoinjector sNDA - simplywall.st
Short Squeeze: Will SHPH stock gain from lower inflation2025 Market WrapUp & Free Weekly Watchlist of Top Performers - moha.gov.vn
The Bull Case For MannKind (MNKD) Could Change Following FDA Review Of FUROSCIX ReadyFlow Autoinjector - simplywall.st
MannKind stock price target raised to $9 by Leerink on Tyvaso DPI royalties - Investing.com
MannKind (NASDAQ:MNKD) CEO Michael Castagna Sells 107,920 Shares of Stock - MarketBeat
MannKind (MNKD) Valuation Check After FDA Filing Progress for FUROSCIX ReadyFlow Autoinjector - simplywall.st
Mannkind EVP Thomson sells $823k in shares By Investing.com - Investing.com South Africa
Insider Selling: Michael Castagna Sells Shares of MannKind Corp (MNKD) - GuruFocus
MNKD FinancialsIncome Statement - Quiver Quantitative
Mannkind EVP Thomson sells $823k in shares - Investing.com
Mannkind CEO Castagna sells $601k in shares By Investing.com - Investing.com UK
Mannkind CEO Castagna sells $601k in shares - Investing.com
MannKind Corp Executives Sell Shares - TradingView — Track All Markets
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):